Patritumab Deruxtecan Application Withdrawn for EGFR-Mutated Lung Cancer
TL;DR Summary
Merck and Daiichi Sankyo have voluntarily withdrawn their Biologics License Application for patritumab deruxtecan for treating EGFR-mutated non-small cell lung cancer after the Phase 3 trial failed to meet overall survival endpoints, despite promising progression-free survival results.
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
11 min
vs 12 min read
Condensed
98%
2,222 → 37 words
Want the full story? Read the original article
Read on Merck.com